Numerous studies in the literature have documented the importance of targeting nuclear factor erythroid-2 related factor 2 (NRF2)/antioxidant signaling and nuclear factor-kappa B (NF-κB) in the inflammatory response, as inflammation is a key factor in many pathological conditions such as cancer. This evidence concerns the gene NFE2L2 and cancer.